J. Goldman & CO LP Aveo Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $4.38 Million - $5.77 Million	-662,260 Reduced 50.23%	656,161 $5.4 Million
Q2 2022 Aug 15, 2022	BUY	$3.51 - $6.67 $29,677 - $56,394	8,455 Added 0.65%	1,318,421 $8.65 Million
Q1 2022 May 16, 2022	BUY	$3.15 - $6.01 $281,005 - $536,140	89,208 Added 7.31%	1,309,966 $7.32 Million
Q4 2021 Feb 14, 2022	SELL	$4.69 - $7.4 $2.08 Million - $3.27 Million	-442,471 Reduced 26.6%	1,220,758 $5.73 Million
Q3 2021 Nov 15, 2021	SELL	$5.12 - $6.89 $808,688 - $1.09 Million	-157,947 Reduced 8.67%	1,663,229 $10.3 Million
Q2 2021 Aug 16, 2021	BUY	$6.21 - $7.45 $11.3 Million - $13.6 Million	1,821,176 New	1,821,176 $12 Million

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.